Psilocybin by Filament Health for Treatment Resistant Depression: Likelihood of Approval

Psilocybin is under clinical development by Filament Health and currently in Phase I for Treatment Resistant Depression.

Celastrol’s druggability, molecular targets, and nanocarrier delivery against chronic diseases

Announcing a new publication for Acta Materia Medica journal. Celastrol is an active compound from the root of Tripterygium wilfordii Hook F that shows great

November 5, 2024

Will Geron be acquired? The long-short view

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their

June 13, 2024

Psychedelics Reform Update From Several States In The Union

Since our previous roundup, whether inside state legislatures or out on the streets, there’s been some consistent movement of proposals concerning psychedelics. As of Sept. 28: Massachusetts:

October 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.